4'epidoxorubicin plus verapamil in anthracycline--refractory cancer patients.
Four patients refractory to doxorubicin (DX) and 9 patients refractory to 4'epidoxorubicin (4'EpiDX) were treated with verapamil (VRP) (120 mg every 6 h for 3 days) plus 4'EpiDX (80 mg/m2 i.v. bolus, together with the 6th VRP administration). Three patients had partial remissions lasting 3, 3.5 and 7 months, respectively. Toxicity grading did not exceed usual levels. The study demonstrates that VRP, when added at conventional doses to 4'EpiDX, can induce objective responses in some patients refractory to anthracyclines.
Demicheli
R
R
Divisione di Radioterapia e Oncologia, U.S.S.L. 28, Legnago, Italy.
Jirillo
A
A
Bonciarelli
G
G
Lonardi
F
F
Balli
M
M
Bandello
A
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004351:Drug Resistance; D015251:Epirubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014700:Verapamil / Q000008:administration & dosage
D015251:Epirubicin; D014700:Verapamil